Non-Invasive Epigenetic Detection of Fetal Trisomy 21 in First Trimester Maternal Plasma

Background Down syndrome (DS) is the most common known aneuploidy, caused by an extra copy of all or part of chromosome 21. Fetal-specific epigenetic markers have been investigated for non-invasive prenatal detection of fetal DS. The phosphodiesterases gene, PDE9A, located on chromosome 21q22.3, is completely methylated in blood (M-PDE9A) and unmethylated in the placenta (U-PDE9A). Therefore, we estimated the accuracy of non-invasive fetal DS detection during the first trimester of pregnancy using this tissue-specific epigenetic characteristic of PDE9A. Methodology/Principal Findings A nested, case-control study was conducted using maternal plasma samples collected from 108 pregnant women carrying 18 DS and 90 normal fetuses (each case was matched with 5 controls according to gestational weeks at blood sampling). All pregnancies were singletons at or before 12 weeks of gestation between October 2008 and May 2009. The maternal plasma levels of M-PDE9A and U-PDE9A were measured by quantitative methylation-specific polymerase chain reaction. M-PDE9A and U-PDE9A levels were obtained in all samples and did not differ between male and female fetuses. M-PDE9A levels did not differ between the DS cases and controls (1854.3 vs 2004.5 copies/mL; P = 0.928). U-PDE9A levels were significantly elevated in women with DS fetuses compared with controls (356.8 vs 194.7 copies/mL, P<0.001). The sensitivities of U-PDE9A level and the unmethylation index of PDE9A for non-invasive fetal DS detection were 77.8% and 83.3%, respectively, with a 5% false-positive rate. In the risk assessment for fetal DS, the adjusted odds ratios of U-PDE9A level and UI were 46.2 [95% confidence interval: 7.8–151.6] and 63.7 [95% confidence interval: 23.2–206.7], respectively. Conclusions Our findings suggest that U-PDE9A level and the unmethylation index of PDE9A may be useful biomarkers for non-invasive fetal DS detection during the first trimester of pregnancy, regardless of fetal gender.

[1]  S. Antonarakis,et al.  Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence , 1998, Human Genetics.

[2]  Y. Li,et al.  Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. , 2004, Clinical chemistry.

[3]  L. Poon,et al.  Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma. , 2002, Clinical chemistry.

[4]  M. Dziegiel,et al.  Improvement in fetal DNA extraction from maternal plasma. Evaluation of the NucliSens Magnetic Extraction system and the QIAamp DSP Virus Kit in comparison with the QIAamp DNA Blood Mini Kit , 2007, Prenatal diagnosis.

[5]  James F. Smith,et al.  Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase* , 1998, The Journal of Biological Chemistry.

[6]  Z. Alfirevic,et al.  Procedure-Related Complications of Amniocentesis and Chorionic Villous Sampling: A Systematic Review , 2007, Obstetrics and gynecology.

[7]  U. Reddy,et al.  Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop. , 2006, Obstetrics and gynecology.

[8]  A. Hui,et al.  Size distributions of maternal and fetal DNA in maternal plasma. , 2004, Clinical chemistry.

[9]  E. Hook,et al.  Chromosomal abnormality rates at amniocentesis and in live-born infants. , 1983, JAMA.

[10]  C. Ding,et al.  Systematic search for placental DNA-methylation markers on chromosome 21: toward a maternal plasma-based epigenetic test for fetal trisomy 21. , 2008, Clinical chemistry.

[11]  S. Y. Park,et al.  Effective detection of fetal sex using circulating fetal DNA in first‐trimester maternal plasma , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  Alex Karagrigoriou,et al.  Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21 , 2011, Nature Medicine.

[13]  T K Lau,et al.  Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. , 1998, American journal of human genetics.

[14]  Tak Y. Leung,et al.  Epigenetic-Genetic Chromosome Dosage Approach for Fetal Trisomy 21 Detection Using an Autosomal Genetic Reference Marker , 2010, PloS one.

[15]  A. Rudnicka,et al.  First-trimester or second-trimester screening, or both, for Down's syndrome. , 2005, New England Journal of Medicine.

[16]  Chunming Ding,et al.  Detection of the placental epigenetic signature of the maspin gene in maternal plasma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Canick,et al.  Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy. , 2003, Clinical chemistry.

[18]  E. Birney,et al.  An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs). , 2008, Genome research.

[19]  Susan Gross,et al.  Clinical practice. Prenatal screening for aneuploidy. , 2009, The New England journal of medicine.

[20]  F. Crea,et al.  Workshop report on the extraction of foetal DNA from maternal plasma , 2007, Prenatal diagnosis.

[21]  J. Beavo,et al.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.

[22]  R. Snijders,et al.  First-trimester screening for trisomies 21 and 18 , 2003 .

[23]  S. Y. Park,et al.  Effective Prediction of Preeclampsia by a Combined Ratio of Angiogenesis-Related Factors , 2008, Obstetrics and gynecology.